drugset
drugset / Trial / NCT02138084

Drug-drug Interaction (DDI) Rifabutin

NCT02138084 ↗

Phase 1 Completed 102 enrolled ViiV Healthcare GlaxoSmithKline · collab
RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to provide dosing recommendations for the coadministration of BMS-663068 and Rifabutin with and without Ritonavir in upcoming Phase 3 studies and for prescribing information purposes

Timeline

Start
2014-05-14
Primary completion
2014-07-24
Completion
2014-07-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Fostemsavir Other / unclassified — Oral
Subject Rifabutin Small molecule — Oral
Subject Ritonavir Other / unclassified — Oral

Indications

HIV infectious disease